Analyze Diet
Frontiers in immunology2022; 13; 871216; doi: 10.3389/fimmu.2022.871216

Production of Cytotoxic Antibodies After Intra-Articular Injection of Allogeneic Synovial Membrane Mesenchymal Stem Cells With and Without LPS Administration.

Abstract: Allogeneic mesenchymal stem cells (MSC) are widely used in clinical routine due to the shorter expansion time and reliability of its quality. However, some recipients can produce alloantibodies that recognize MSCs and activate the immune system, resulting in cell death. Although antibody production was already described after MSC injection, no previous studies described the immune response after intra-articular MSC injection in acute synovitis. This study aimed to evaluate the influence of inflammation on immune response after single and repeated intra-articular injections of synovial membrane MSC (SMMSC). Horses were divided in three groups: control group (AUTO) received autologous synovial membrane MSCs; whereas group two (ALLO) received allogeneic SMMSCs and group three (ALLO LPS) was submitted to acute experimental synovitis 8 h before SMMSCs injection. The procedure was repeated for all groups for 28 days. Physical and lameness evaluations and synovial fluid analysis were performed. Sera from all animals were obtained before and every 7 days after each injection up to 4 weeks, to perform microcytotoxicity assays incubating donor SMMSCs with recipients' sera. The first injection caused a mild and transient synovitis in all groups, becoming more evident and longer in ALLO and ALLO LPS groups after the second injection. Microcytotoxicity assays revealed significant antibody production as soon as 7 days after SMMSC injection in ALLO and ALLO LPS groups, and cytotoxicity scores of both groups showed no differences at any time point, being equally different from AUTO group. Although inflammation is capable of inducing MHC expression in MSCs, which enhances immune recognition, cytotoxicity scores were equally high in ALLO and ALLO LPS groups, making it difficult to determine the potentiation effect of inflammation on antibody production. Our findings suggest that inflammation does not display a pivotal role in immune recognition on first allogeneic MSC injection. In a translational way, since specific antibodies were produced against MSCs, patients that need more than one MSC injection may benefit from a first allogeneic injection followed by subsequent autologous injections.
Publication Date: 2022-04-27 PubMed ID: 35572507PubMed Central: PMC9091817DOI: 10.3389/fimmu.2022.871216Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates the antibody response to single and repeated injections of allogeneic synovial membrane mesenchymal stem cells (SMMSCs) in the treatment of acute synovitis. It suggests that inflammation does not play a major role in the immune response against the first allogeneic MSC injection, and patients requiring multiple MSC injections might benefit from an initial allogeneic injection succeeded by autologous injections.

Objective and Methodology

  • The study aims to understand how inflammation impacts the immune response after single or repeated injections of SMMSCs directly into the joint (intra-articular).
  • The experiment consisted of three groups of horses: a control group (AUTO) received autologous SMMSCs, ALLO received allogeneic SMMSCs, and ALLO LPS underwent acute experimental synovitis before receiving the SMMSCs injection.
  • This procedure was replicated for all groups over 28 days, with physical and lameness evaluations and synovial fluid analysis conducted.
  • Blood samples were collected from all participants before and after each injection at 7-day intervals for analysis of microcytotoxicity to determine antibody production.

Key Findings

  • All groups demonstrated a slight and brief inflammation after the first injection, with the ALLO and ALLO LPS groups showing more pronounced and extended inflammation after the second injection.
  • Evidence of significant antibody production was noticed as early as 7 days post injection in both the ALLO and ALLO LPS groups, with no remarkable variations in cytotoxicity scores among them.
  • Despite the potential of inflammation to enhance immune recognition via MHC expression in MSCs, the cytotoxicity levels were nearly identical in the ALLO and ALLO LPS groups, obscuring any potential effect of inflammation on antibody production.

Implications

  • The study suggests that inflammation does not play a significant role in immune recognition during the first allogeneic MSC injection.
  • In terms of medical application, as specific antibodies were produced against MSCs, patients requiring multiple MSC injections might benefit from an initial allogeneic injection, followed by autologous injections.

Cite This Article

APA
Rosa GDS, Krieck AMT, Padula ET, Stievani FC, Rossi MC, Pfeifer JPH, Basso RM, Braz AMM, Golim MA, Alves ALG. (2022). Production of Cytotoxic Antibodies After Intra-Articular Injection of Allogeneic Synovial Membrane Mesenchymal Stem Cells With and Without LPS Administration. Front Immunol, 13, 871216. https://doi.org/10.3389/fimmu.2022.871216

Publication

ISSN: 1664-3224
NlmUniqueID: 101560960
Country: Switzerland
Language: English
Volume: 13
Pages: 871216
PII: 871216

Researcher Affiliations

Rosa, Gustavo Dos Santos
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Krieck, André Massahiro Teramoto
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Padula, Enrico Topan
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Stievani, Fernanda de Castro
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Rossi, Mariana Correa
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Pfeifer, João Pedro Hübbe
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Basso, Roberta Martins
  • Department of Veterinary Clinics, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.
Braz, Aline Márcia Marques
  • Flow Cytometry Laboratory, Applied Biotechnology Laboratory, Clinical Hospital of Botucatu Medical School, Botucatu, Brazil.
Golim, Márjorie de Assis
  • Flow Cytometry Laboratory, Applied Biotechnology Laboratory, Clinical Hospital of Botucatu Medical School, Botucatu, Brazil.
  • Graduate Program in Research and Development (Medical Biotechnology), Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil.
Alves, Ana Liz Garcia
  • Department of Veterinary Surgery and Animal Reproduction, Regenerative Medicine Lab, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, Brazil.

MeSH Terms

  • Animals
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Horses
  • Humans
  • Inflammation / complications
  • Injections, Intra-Articular / adverse effects
  • Lipopolysaccharides
  • Mesenchymal Stem Cell Transplantation / methods
  • Mesenchymal Stem Cells
  • Reproducibility of Results
  • Synovial Membrane
  • Synovitis / chemically induced
  • Synovitis / therapy

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 35 references
  1. Ilic D, Polak J. Stem cell based therapy--where are we going?. Lancet 2012 Mar 10;379(9819):877-878.
    doi: 10.1016/S0140-6736(12)60155-Xpubmed: 22405784google scholar: lookup
  2. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.. Exp Hematol 2002 Jan;30(1):42-8.
    doi: 10.1016/S0301-472X(01)00769-Xpubmed: 11823036google scholar: lookup
  3. Ankrum JA, Ong JF, Karp JM. Mesenchymal Stem Cells: Immune Evasive, Not Immune Privileged. Nat Biotechnol 2014 32:252–60.
    doi: 10.1038/nbt.2816google scholar: lookup
  4. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  5. Owens SD, Kol A, Walker NJ, Borjesson DL. Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses.. Stem Cells Int 2016;2016:5830103.
    doi: 10.1155/2016/5830103pmc: PMC5018342pubmed: 27648075google scholar: lookup
  6. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  7. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  8. Maki CB, Beck A, Wallis CCC, Choo J, Ramos T, Tong R, Borjesson DL, Izadyar F. Intra-articular Administration of Allogeneic Adipose Derived MSCs Reduces Pain and Lameness in Dogs With Hip Osteoarthritis: A Double Blinded, Randomized, Placebo Controlled Pilot Study.. Front Vet Sci 2020;7:570.
    doi: 10.3389/fvets.2020.00570pmc: PMC7489271pubmed: 33110913google scholar: lookup
  9. Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.. Vet Immunol Immunopathol 2013 Nov 15;156(1-2):99-106.
    doi: 10.1016/j.vetimm.2013.09.003pubmed: 24094688google scholar: lookup
  10. Boone L. Intra-Articular Administration of Allogeneic Equine Bone Marrow Derived Mesenchymal Stem Cells. Athens, Georgia: University of Georgia; (2013).
  11. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  12. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function.. J Neurosci 2010 Jul 14;30(28):9603-11.
  13. Hatsushika D, Muneta T, Nakamura T, Horie M, Koga H, Nakagawa Y, Tsuji K, Hishikawa S, Kobayashi E, Sekiya I. Repetitive allogeneic intraarticular injections of synovial mesenchymal stem cells promote meniscus regeneration in a porcine massive meniscus defect model.. Osteoarthritis Cartilage 2014 Jul;22(7):941-50.
    doi: 10.1016/j.joca.2014.04.028pubmed: 24795274google scholar: lookup
  14. Brandão JS, Alvarenga ML, Pfeifer JPH, Dos Santos VH, Fonseca-Alves CE, Rodrigues M, Laufer-Amorim R, Castillo JAL, Alves ALG. Allogeneic mesenchymal stem cell transplantation in healthy equine superficial digital flexor tendon: A study of the local inflammatory response.. Res Vet Sci 2018 Jun;118:423-430.
    doi: 10.1016/j.rvsc.2018.03.012pubmed: 29715649google scholar: lookup
  15. Barrachina L, Cequier A, Romero A, Vitoria A, Zaragoza P, Vázquez FJ, Rodellar C. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.. Stem Cell Res Ther 2020 Feb 7;11(1):52.
    doi: 10.1186/s13287-020-1571-8pmc: PMC7006079pubmed: 32028995google scholar: lookup
  16. Ryan SO, Cobb BA. Roles for major histocompatibility complex glycosylation in immune function.. Semin Immunopathol 2012 May;34(3):425-41.
    doi: 10.1007/s00281-012-0309-9pmc: PMC3884644pubmed: 22461020google scholar: lookup
  17. Guest DJ, Ousey JC, Smith MR. Defining the expression of marker genes in equine mesenchymal stromal cells.. Stem Cells Cloning 2008;1:1-9.
    doi: 10.2147/SCCAA.S3824pmc: PMC3781685pubmed: 24198500google scholar: lookup
  18. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages.. Annu Rev Immunol 1999;17:593-623.
  19. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  20. Mochizuki T, Muneta T, Sakaguchi Y, Nimura A, Yokoyama A, Koga H, Sekiya I. Higher chondrogenic potential of fibrous synovium- and adipose synovium-derived cells compared with subcutaneous fat-derived cells: distinguishing properties of mesenchymal stem cells in humans.. Arthritis Rheum 2006 Mar;54(3):843-53.
    doi: 10.1002/art.21651pubmed: 16508965google scholar: lookup
  21. Kondo S, Muneta T, Nakagawa Y, Koga H, Watanabe T, Tsuji K, Sotome S, Okawa A, Kiuchi S, Ono H, Mizuno M, Sekiya I. Transplantation of autologous synovial mesenchymal stem cells promotes meniscus regeneration in aged primates.. J Orthop Res 2017 Jun;35(6):1274-1282.
    doi: 10.1002/jor.23211pubmed: 26916126google scholar: lookup
  22. Koch TG, Betts DH. Stem cell therapy for joint problems using the horse as a clinically relevant animal model.. Expert Opin Biol Ther 2007 Nov;7(11):1621-6.
    doi: 10.1517/14712598.7.11.1621pubmed: 17961087google scholar: lookup
  23. Colbath AC, Frisbie DD, Dow SW, Kisiday JD, McIlwraith CW, Goodrich LR. Equine Models for the Investigation of Mesenchymal Stem Cell Therapies in Orthopaedic Disease. Oper Tech Sports Med 2017 25:41–9.
  24. Ribitsch I, Baptista PM, Lange-Consiglio A, Melotti L, Patruno M, Jenner F, Schnabl-Feichter E, Dutton LC, Connolly DJ, van Steenbeek FG, Dudhia J, Penning LC. Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do.. Front Bioeng Biotechnol 2020;8:972.
    doi: 10.3389/fbioe.2020.00972pmc: PMC7438731pubmed: 32903631google scholar: lookup
  25. Williams LB, Koenig JB, Black B, Gibson TWG, Sharif S, Koch TG. Equine Allogeneic Umbilical Cord Blood Derived Mesenchymal Stromal Cells Reduce Synovial Fluid Nucleated Cell Count and Induce Mild Self-Limiting Inflammation When Evaluated in a Lipopolysaccharide Induced Synovitis Model. Equine Vet J 2016 48:619–25.
    doi: 10.1111/evj.12477google scholar: lookup
  26. Li W, Ren G, Huang Y, Su J, Han Y, Li J. Mesenchymal Stem Cells: A Double-Edged Sword in Regulating Immune Responses. Cell Death Differ 2012 19:1505–13.
    doi: 10.1038/cdd.2012.26google scholar: lookup
  27. Selvaggi TA, Walker RE, Fleisher TA. Development of Antibodies to Fetal Calf Serum With Arthus-Like Reactions in Human Immunodeficiency Virus-Infected Patients Given Syngeneic Lymphocyte Infusions. Blood 1997 89:776–9.
    doi: 10.1182/blood.V89.3.776google scholar: lookup
  28. Mackensen A, Dräger R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE Antibodies to Bovine Serum Albumin in a Patient Developing Anaphylaxis After Vaccination With Human Peptide-Pulsed Dendritic Cells. Cancer Immunol Immunother 2000 49:152–6.
    doi: 10.1007/s002620050614google scholar: lookup
  29. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.. Stem Cell Res Ther 2014 Jul 30;5(4):90.
    doi: 10.1186/scrt479pmc: PMC4247727pubmed: 25080326google scholar: lookup
  30. Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.. Stem Cells Transl Med 2021 May;10(5):694-710.
    doi: 10.1002/sctm.20-0435pmc: PMC8046071pubmed: 33369287google scholar: lookup
  31. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response.. Biol Blood Marrow Transplant 2007 Apr;13(4):412-22.
    doi: 10.1016/j.bbmt.2006.12.447pmc: PMC1892590pubmed: 17382248google scholar: lookup
  32. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo.. Transplantation 2007 Mar 27;83(6):783-90.
  33. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, Kündig TM, Gander B, Johansen P. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.. J Control Release 2010 Nov 1;147(3):342-9.
    doi: 10.1016/j.jconrel.2010.08.012pubmed: 20727926google scholar: lookup
  34. Uchi H, Terao H, Koga T, Furue M. Cytokines and chemokines in the epidermis.. J Dermatol Sci 2000 Dec;24 Suppl 1:S29-38.
    doi: 10.1016/S0923-1811(00)00138-9pubmed: 11137393google scholar: lookup
  35. Kawase A, Isaji K, Yamaoka A, Kobayashi N, Nishikawa M, Takakura Y. Enhanced antigen-specific antibody production following polyplex-based DNA vaccination via the intradermal route in mice.. Vaccine 2006 Jul 7;24(27-28):5535-45.
    doi: 10.1016/j.vaccine.2006.04.056pubmed: 16716462google scholar: lookup

Citations

This article has been cited 3 times.
  1. Punzón E, García-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial.. Front Vet Sci 2023;10:1098029.
    doi: 10.3389/fvets.2023.1098029pubmed: 37266387google scholar: lookup
  2. Copp G, Robb KP, Viswanathan S. Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success.. Cell Mol Immunol 2023 Jun;20(6):626-650.
    doi: 10.1038/s41423-023-01020-1pubmed: 37095295google scholar: lookup
  3. Fan M, Zhang J, Zhou L, Chen Z, Bao R, Zheng L, Tong P, Ma Y, Shan L. Intra-articular injection of placental mesenchymal stromal cells ameliorates pain and cartilage anabolism/catabolism in knee osteoarthritis.. Front Pharmacol 2022;13:983850.
    doi: 10.3389/fphar.2022.983850pubmed: 36523496google scholar: lookup